RA Capital Nexus Fund II, L.P. is 10% Owner at AN2 Therapeutics, Inc. (ANTX). They have made 9 open-market trades across 7 companies since 2021, most recently 2025-05-14.
CIK 0001825376
9 open-market purchases totalling $141.5M since 2021, never a sale. Across 9 scored buys the stock is up 9.8% at ninety days, and 7.8 points ahead of the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 56% | 56% | 67% |
| Avg Move | +8.4% | +10.0% | +9.8% |
| Alpha | +7.7% | +9.3% | +7.8% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| HOWL | BUY | 2025-05-12 | 2025-05-14 | $0.91 | $974K | +0.8% | +3.4% | +1.7% |
| LENZ | BUY | 2024-03-21 | 2024-03-25 | $15.03 | $30.0M | +20.1% | -6.3% | +7.1% |
| ANTX | BUY | 2023-08-18 | 2023-08-22 | $9.00 | $16.0M | +3.2% | -6.6% | +10.9% |
| JANX | BUY | 2023-07-19 | 2023-07-21 | $12.46 | $12.3M | -4.6% | -15.5% | -46.8% |
| DICE | BUY | 2023-03-28 | 2023-03-30 | $29.07 | $29.6M | -9.0% | +14.5% | +55.7% |
| ANTX | BUY | 2022-07-26 | 2022-07-28 | $7.78 | $361K | +34.9% | +68.6% | +78.5% |
| ANTX | BUY | 2022-06-13 | 2022-06-15 | $7.96 | $1.1M | -6.9% | +1.8% | -4.0% |
| CTKB | BUY | 2022-02-23 | 2022-02-25 | $13.22 | $11.1M | -1.4% | -25.1% | -26.6% |
| ELYM | BUY | 2021-08-12 | 2021-08-16 | $12.50 | $40.0M | +38.6% | +55.1% | +12.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total | $565.7M |
Shares reported on the most recent Form 4, priced at the 2025-05-14 close.